Displaying items 81-82 of 82 in total
eDreams ODIGEO is cancelling millions of shares, powered by its Prime subscription model. But can it sustain aggressive buybacks while chasing growth?
After its RELYVRIO setback, Amylyx's next-gen ALS drug AMX0114 clears a key safety hurdle. Is this the strategic pivot investors have been waiting for?
Get your daily brief delivered to your inbox every morning at 7am
